LEADER: Liraglutide lowers CVD risk in type 2 diabetes
Liraglutide is associated with a decreased risk of cardiovascular events, compared with placebo, in individuals with type 2 diabetes, according to results from the randomized, placebo-controlled,...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Victoza